Monday, February 22, 2021 12:27:30 PM
Stock Jodi , actually , I will agree with this request to some point in very early infection only ,
Just not alone with Bamlanivimab , since lately study in monotherapy showed no effect..
All these neutralizing monoclonal antibodies working at the very beginning of covid on spike protein of the virus ..
I remember with REGN-cov2 about 50% of virus could be neutralized , and then our body should be strong enough to get rid of rest , or patients will go to the immunological stage and it will need other drugs as Leronlimab...
REGN-cov2 has 2 different neutralizing antibodies , each working on different area of spike protein , so is little less sensitive to mutations.
Lets look at President Trump treatment .
In AM they gave him REGN-covid2 , he was getting worse so in the evening they started 5 days therapy with Remdesivir.
Still 2 days later his lung scan show beginning of inflammation , blood oxygen went down < 93 % , and doctors added dexamethasone..
I believe that if they give him REGN-cov2 plus Leronlimab he will not need anything else..
Actually I believe that only Leronlimab will do the job , but I will not completely object to REGN-cov2 given with Leronlimab at the beginning of this disease , as I am objecting to using with Remdesivir..
Lets remember , neutralizing monoclonal antibodies decrease VL ( if ) , when given early , but they do nothing else , they do not work on our immunological system ,
and they may have some side effects , including severe allergic reaction.
This is why infusion is done for about one hour , and then 2-3 hrs observation...
This is All IMO.
Just not alone with Bamlanivimab , since lately study in monotherapy showed no effect..
All these neutralizing monoclonal antibodies working at the very beginning of covid on spike protein of the virus ..
I remember with REGN-cov2 about 50% of virus could be neutralized , and then our body should be strong enough to get rid of rest , or patients will go to the immunological stage and it will need other drugs as Leronlimab...
REGN-cov2 has 2 different neutralizing antibodies , each working on different area of spike protein , so is little less sensitive to mutations.
Lets look at President Trump treatment .
In AM they gave him REGN-covid2 , he was getting worse so in the evening they started 5 days therapy with Remdesivir.
Still 2 days later his lung scan show beginning of inflammation , blood oxygen went down < 93 % , and doctors added dexamethasone..
I believe that if they give him REGN-cov2 plus Leronlimab he will not need anything else..
Actually I believe that only Leronlimab will do the job , but I will not completely object to REGN-cov2 given with Leronlimab at the beginning of this disease , as I am objecting to using with Remdesivir..
Lets remember , neutralizing monoclonal antibodies decrease VL ( if ) , when given early , but they do nothing else , they do not work on our immunological system ,
and they may have some side effects , including severe allergic reaction.
This is why infusion is done for about one hour , and then 2-3 hrs observation...
This is All IMO.
Recent CYDY News
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
